| Bone Mineral Density Changes During Androgen Deprivation Therapy for
Patients with Prostate Cancer |
| 남성호르몬차단요법을 시행한 전립선암 환자에서의
골밀도 변화 |
| 이승준,이동길,박정현,김재한,송강현,박종욱,길명철,조문기 |
| 원자력병원 비뇨기과 |
|
|
| Abstract |
Purpose
Androgen deprivation therapy (ADT) improves survival of patients with prostate cancer but leads to
hypogonadal state. Gonadal hormones are essential for bone integrity and hypogonadism from ADT constitutes a major
risk factor for osteoporosis. We investigated bone mineral density (BMD) changes according to duration of ADT and
other clinical factors.
Methods
A total of 102 patients with prostate cancer receiving ADT and 37 men of controls were evaluated. Dual
energy x-ray absorptiometry was used to assess BMD at the lumbar spine. Age, body mass index (BMI), BMD, Gleason
score, initial prostate-specific antigen (PSA), duration of ADT, smoking history, history of diabetes mellitus (DM),
hypertension and preventive therapy of osteoporosis were obtained and analyzed.
Results
BMD of prostate cancer patients with ADT was significantly lower than that of controls. Old age and low
BMI were correlated with low BMD. Longer duration of ADT made more decrease in BMD of prostate cancer patients
receiving ADT. Preventive therapy of osteoporosis during ADT showed significant correlation with high BMD and also
decreased bone mass loss rate per year.
Conclusions
Our study indicated that BMD was associated with ADT and its duration. Anti-osteoporotic therapy could
decrease bone mass loss. Therefore we suggest that clinicians should be aware of impact of ADT on BMD to prevent
osteoporosis. [Korean Journal of Bone Metabolism, 16(2): 79-85, 2009] |
| Key Words:
Bone density, Osteoporosis, Prostatic neoplasms, Androgens |
|
PDF Links
Full text via DOI
Download Citation
